Promoted Content
Promoted Content

Find Psychiatry/Psychology Drugs in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSD

            Therapeutic Area: Psychiatry/Psychology Product Name: LSD

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Canaccord Genuity Corp

            Deal Size: $62.8 million Upfront Cash: Undisclosed

            Deal Type: Financing December 21, 2020

            Details:

            Net proceeds of the Offering will be used in the company's digital medicine division, its development of a non-hallucinogenic version of the psychedelic ibogaine to address the opioid crisis, and its LSD micro-dosing trials for adult ADHD and for general working capital.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vafidemstat

            Therapeutic Area: Psychiatry/Psychology Product Name: ORY-2001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oryzon Genomics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 17, 2020

            Details:

            Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brilaroxazine

            Therapeutic Area: Psychiatry/Psychology Product Name: RP5063

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tenzing Acquisition

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger December 14, 2020

            Details:

            As a result of the completion of the Business Combination, Reviva has become a wholly-owned subsidiary of Reviva Holdings, as the successor to Tenzing. Post merger, the combined company will first look to advance its late-stage lead asset Brilaroxazine (RP5063).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lind Global Asset Management

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Private Placement December 14, 2020

            Details:

            Seelos intends to use the proceeds for general corporate purposes and to advance the development of its product candidates, including the acute suicidal ideation and behavior trial for SLS-002.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRAX-114

            Therapeutic Area: Psychiatry/Psychology Product Name: PRAX-114

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            FDA proposed that the Company conduct further toxicological investigation of the effect of PRAX-114 and its metabolites on fertility, reproduction, and embryofetal development to support the planned trial. Praxis expects to start Phase 2/3 trial for PRAX-114 in MDD in 1H21.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Radix Polygalae extract,PDC-1421

            Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1505

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRAX-114

            Therapeutic Area: Psychiatry/Psychology Product Name: PRAX-114

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            Praxis has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD). FDA notified the Company that the IND has been placed on full clinical hold.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSD

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Experiential dose of 200 ug LSD was shown to induce greater ego dissolution than a lesser 100 ug dose. The completed Phase 1 study will help MindMed in dose-finding and planning the future Phase 2 clinical trials of LSD in patients with anxiety disorders and other conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SXC-2023

            Therapeutic Area: Psychiatry/Psychology Product Name: SXC-2023

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 31, 2020

            Details:

            The presentation will highlight the continued safety and psychometric activity of the company's lead clinical molecule, SXC-2023, a drug designed to restore cognitive control over repetitive, maladaptive behaviors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRAX-114

            Therapeutic Area: Psychiatry/Psychology Product Name: PRAX-114

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cowen

            Deal Size: $190.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering October 15, 2020

            Details:

            The IPO proceeds will bankroll the phase 2a and phase 2/3 trials of lead asset PRAX-114, an oral modulator of GABAA receptors, according to a securities filing.